Chondrogard solution for injection 100mg / ml, 2ml No. 25

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of the peripheral joints;

• intervertebral osteochondrosis and osteoarthritis.

• To accelerate the formation of callus in fractures.

The drug is prescribed intramuscularly at 100 mg every other day. With good tolerance, the dose is increased to 200 mg, starting with the 4th injection. The course of treatment is 25-30 injections. If necessary, a second course of treatment is possible after 6 months.

With osteoarthritis of large joints, a combination of intra-articular and intramuscular routes of administration is possible. Up to 5 intra-articular injections of 200 mg are carried out with an interval of 3 days between injections and 16 i / m injections of 200 mg with an interval of 1 day between injections (every other day).

Intra-articular administration of the drug is carried out under aseptic conditions by a specialist trained in the technique of intra-articular administration. Depending on the size of the joint, up to 2 ml of ChondroguardЃ can be injected into the articular cavity. After intra-articular injection of the drug, the puncture site is lubricated with an alcohol napkin, a bactericidal patch is applied. For the formation of callus, the course of treatment is 3-4 weeks (10-14 intramuscular injections every other day).

The solution for i / m and intra-articular administration is transparent, colorless or slightly yellowish, with the smell of benzyl alcohol.

1 ml

chondroitin sodium sulfate 100 mg

Excipients: benzyl alcohol, sodium metabisulfite, sodium hydroxide - up to pH 6.0-7.5, water d / i - up to 1 ml.

• Hypersensitivity to the components of the drug;

• bleeding and bleeding tendency;

• thrombophlebitis;

• with intra-articular administration, the presence of active inflammatory or infectious processes in the joint, the presence of an active skin disease or skin infection in the area of ??the intended injection;

• childhood;

• pregnancy (data on the safety of the drug are currently not available);

• lactation period (data on the safety of the drug are currently not available).

pharmachologic effect

High molecular weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. Reduces degenerative changes in the cartilage tissue of the joints, accelerates the processes of its recovery, stimulates the synthesis of proteoglycans.

Treatment with the drug reduces pain and improves the mobility of the affected joints. In the treatment of degenerative changes in the joints with the development of secondary synovitis, a positive effect can be observed as early as 2-3 weeks after the start of drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, and the range of motion in the affected joints increases. The therapeutic effect lasts a long time after the end of the course of treatment.

Pharmacokinetics

After i / m administration of chondroitin, sulfate is rapidly distributed. Within 30 minutes after injection, it is found in the blood in significant concentrations. Cmax of chondroitin sulfate in plasma is reached after 1 hour, then gradually decreases within 2 days.

Chondroitin sulfate accumulates mainly in the cartilage tissue of the joints. The synovium is not an obstacle to the penetration of the drug into the joint cavity. Experiments have shown that 15 minutes after the i / m injection of chondroitin sulfate is found in the synovial fluid, then penetrates into the articular cartilage, where its Cmax is reached after 48 hours.

With intra-articular administration, chondroitin sulfate is retained in the tissues of the joint and its gradual release into the bloodstream. With a single intra-articular administration of the drug ChondroguardЃ at a dose of 200 mg, Cmax of chondroitin sulfate in plasma is observed after 1-2 hours and is 52.5-86.9 ng / ml, T1 / 2 is 2.5 hours.

Side effect

Allergic reactions: pruritus, erythema, urticaria, dermatitis.

Local reactions: hemorrhages at the injection site.

Application during pregnancy and lactation

Contraindicated for use during pregnancy and lactation (data on the safety of the drug are currently not available).

Application in children

Contraindicated for use in childhood.

special instructions

Use in pediatrics

There are currently no data on the efficacy and safety of chondroitin sulfate in children.

Overdose

Currently, no cases of overdose of chondroitin sulfate have been reported.

Drug interactions

It is possible to enhance the action of indirect anticoagulants, antiplatelet agents, fibrinolytics, which requires more frequent monitoring of blood clotting indicators with simultaneous use.